SlideShare a Scribd company logo
1 of 16
Download to read offline
Zaragoza, 27-28 April 2017
A patient perspective on HTA involvement
Valentina Strammiello
Programme Managerr
PUBLIC HEALTH CONFERENCE
10th anniversary of the Spanish Network of Health Technology Assessment (HTA) Agencies:
Insights for collaborative networking
Towards Patient and public engagement in HTA
European Patients’ Forum:
• Umbrella organisation
• active since 2003
• 74 member organisations
Mission
“To ensure that the patient community drives health policies and
programmes that are adapted for their final users, patients.”
EPF’s vision is high-quality, patient-centred, and equitable health and
social care for all patients across the EU.
GOAL #2 To contribute to improvements in health systems that enable
equitable access to sustainable and high-quality healthcare designed and
delivered to meet patients’ and informal carers’ needs at all levels of care,
embracing innovation in all its forms
About EPF
Helicopter view of patient involvement in HTA in
other European HTA agencies or (should be
working)
Who and how is involved or should be involved, in
which stages of the HTA
Main difficulties and challenges faced in patient
engagement in HTA for a proper patient
participation and how they could be addressed
Overview of my presentation
 Availability of funds/affordability
 NHS system (full universal coverage? Bismarckian?
Beveridge?)
 Who conducts the assessments? Who decides?
 Some MS have independent review bodies, others
have entities under government mandates
No standard methodology at EU level (yet)
 Technologies considered for HTA (pharma products and/or
medical devices, procedures etc)
Helicopter view of patient involvement in HTA in
other European HTA agencies
= chronic condition ≠ treatments
Who did it first in Europe?
France and Spain
Started in the early ’80
• Since 2016 France –through HAS
(Haute Autorité de Santé)- has started a pilot project on
patient involvement in HTA
• In a questionnaire patients assess whether treatments
meet their expectations, report how they cope with their
conditions, and impact on quality of life
• The project focuses on selected conditions
• So far results seems not to be optimal for patient
organisations
Institute for Quality and Efficiency in Health Care (IQWiG)
(assessments)
Federal Joint Committee- G-BA (appraisals)
Procedures: inclusive priority setting
G-BA sub-committees appraise evidence (patients*
included, but no voting rights)
• G-BA board issues binding decision for sickness funds
• If patient representative’s position differs from the
board’s decision, this is noted in final documentation
and they may take part in press conference to explain
their position
*Nominated by national umbrella organisation of self-help
groups – pool of approximately 300
Who claims they do it better
Germany
• IQWiG generally invites patient reps to provide
input, mainly when patient-relevant outcomes are
defined for a protocol
• Anyone can submit comments on IQWiG draft
protocols and draft reviews during 4-week
consultation period
• GBA makes open requests for evidence on website
and posts to stakeholders (including patient
organisations) allowing 1 month for submission
Patient input in Germany
• NHS Centre for Reviews and Dissemination (Assessments)
• National Institute for Health and Clinical Excellence
(Appraisals)
– Patient involvement units
• Scottish Medicines Consortium (SMC)
– Decision making Committees
– Involvement of lay citizens/ patient representatives
– National policy that patients must be involved in healthcare
decision-making
– SMC Patient & Public Involvement Group (PAPIG)
– Development of submission form for patients
– Public Involvement Officer supports evidence submissions and
provides feedback
– Plain English explanations of SMC process
Who does it better?
UK- England and Scotland
Rationale: lack of resources to ensure patients access to
innovative technologies
Countries involved:
– Bulgaria (lead), Croatia, Hungary, Romania, Slovakia
• But in the future also: Bosnia and Herzegovina,
Macedonia, Serbia, Slovenia
– Who is involved in the Think Tank:
• Experts, medical doctors, pharmaco-economists,
and representatives from patient associations
A bottom up regional initiative in Eastern Europe
Central Eastern Europe Think Tank on Patient Access-CEE
TTPA
• HTA Network Patient and Consumer
Stakeholder Pool
• Patients organisations collaborating with
EUnetHTA
• EPF informal Working Group on HTA
• HTAi PCIG-Patient Panel
Patients actions at EU/international level
Who and how is involved or should be
involved, in which stages of the HTA
Patient involvement in HTA
• Scoping
• Prioritisation
• Assessment
• Follow up
• Role of patient
organisations
and individual
patients
• not a thick the
box exercise
Patient involvement in the HTA life cycle
• Time
• Language
• Patients perceived as a burden /passive actor
• Involve and inform about the full life cycle
• Education
• Build connection with patient organisations
Challenges faced in patient engagement in HTA
for a proper patient participation
/europeanpatientsforum
/eupatientsforum
More information
www.eu-patient.eu
info@eu-patient.eu
THANK YOU FOR YOUR ATTENTION!
Follow us on Social Media!
/eupatient
eu-patient.eu/blog

More Related Content

What's hot

Good practices in patient involvement in HTA
Good practices in patient involvement in HTAGood practices in patient involvement in HTA
Good practices in patient involvement in HTAEUPATI
 
Is there patient involvement in HTA? Can patients influence HTA decision making?
Is there patient involvement in HTA? Can patients influence HTA decision making?Is there patient involvement in HTA? Can patients influence HTA decision making?
Is there patient involvement in HTA? Can patients influence HTA decision making?Kathi Apostolidis
 
Consumer involvement: Patient views on participation in HTA
Consumer involvement: Patient views on participation in HTAConsumer involvement: Patient views on participation in HTA
Consumer involvement: Patient views on participation in HTACochrane.Collaboration
 
Drug development and treatment strategies may go hand in hand.
Drug development and treatment strategies may go hand in hand.Drug development and treatment strategies may go hand in hand.
Drug development and treatment strategies may go hand in hand.EUPATI
 
Patients’ voice in access decisions
Patients’ voice in access decisionsPatients’ voice in access decisions
Patients’ voice in access decisionsEUPATI
 
Health Technology Assessment
Health Technology AssessmentHealth Technology Assessment
Health Technology AssessmentEUPATI
 
Webinar: Guidance on Industry-led R&D
Webinar: Guidance on Industry-led R&DWebinar: Guidance on Industry-led R&D
Webinar: Guidance on Industry-led R&DHibernia College
 
Workshop 2 - "Presentation of the concept, definitions and terminology"
Workshop 2  - "Presentation of the concept, definitions and terminology" Workshop 2  - "Presentation of the concept, definitions and terminology"
Workshop 2 - "Presentation of the concept, definitions and terminology" EURORDIS - Rare Diseases Europe
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
The patients' contribution to ethics committees in the Netherlands
The patients' contribution to ethics committees in the NetherlandsThe patients' contribution to ethics committees in the Netherlands
The patients' contribution to ethics committees in the NetherlandsEUPATI
 
Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...jangeissler
 
Webinar on EUPATI Guidance for Patient Involvement in Ethical Review of Clini...
Webinar on EUPATI Guidance for Patient Involvement in Ethical Review of Clini...Webinar on EUPATI Guidance for Patient Involvement in Ethical Review of Clini...
Webinar on EUPATI Guidance for Patient Involvement in Ethical Review of Clini...Hibernia College
 
Webinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
Webinar on EUPATI Guidance on Patient Involvement in Regulatory ProcessesWebinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
Webinar on EUPATI Guidance on Patient Involvement in Regulatory ProcessesHibernia College
 
Making use of various information systems to disseminate HTA knowledge in France
Making use of various information systems to disseminate HTA knowledge in FranceMaking use of various information systems to disseminate HTA knowledge in France
Making use of various information systems to disseminate HTA knowledge in FranceHaute Autorité de Santé
 
Patient involvement prior to regulatory Scientific Advice
Patient involvement prior to regulatory Scientific AdvicePatient involvement prior to regulatory Scientific Advice
Patient involvement prior to regulatory Scientific AdviceEUPATI
 

What's hot (20)

Jornadas #PatientInHTA · Yolanda Triñanes
Jornadas #PatientInHTA · Yolanda TriñanesJornadas #PatientInHTA · Yolanda Triñanes
Jornadas #PatientInHTA · Yolanda Triñanes
 
Jornadas #PatientInHTA · Nicholas Brooke
Jornadas #PatientInHTA · Nicholas BrookeJornadas #PatientInHTA · Nicholas Brooke
Jornadas #PatientInHTA · Nicholas Brooke
 
Jornadas #PatientInHTA ·Ruth Ubago
Jornadas #PatientInHTA ·Ruth UbagoJornadas #PatientInHTA ·Ruth Ubago
Jornadas #PatientInHTA ·Ruth Ubago
 
Good practices in patient involvement in HTA
Good practices in patient involvement in HTAGood practices in patient involvement in HTA
Good practices in patient involvement in HTA
 
Jornadas #PatientInHTA · Gaizka Benguria
Jornadas #PatientInHTA · Gaizka BenguriaJornadas #PatientInHTA · Gaizka Benguria
Jornadas #PatientInHTA · Gaizka Benguria
 
Is there patient involvement in HTA? Can patients influence HTA decision making?
Is there patient involvement in HTA? Can patients influence HTA decision making?Is there patient involvement in HTA? Can patients influence HTA decision making?
Is there patient involvement in HTA? Can patients influence HTA decision making?
 
Consumer involvement: Patient views on participation in HTA
Consumer involvement: Patient views on participation in HTAConsumer involvement: Patient views on participation in HTA
Consumer involvement: Patient views on participation in HTA
 
Drug development and treatment strategies may go hand in hand.
Drug development and treatment strategies may go hand in hand.Drug development and treatment strategies may go hand in hand.
Drug development and treatment strategies may go hand in hand.
 
Patients’ voice in access decisions
Patients’ voice in access decisionsPatients’ voice in access decisions
Patients’ voice in access decisions
 
Health Technology Assessment
Health Technology AssessmentHealth Technology Assessment
Health Technology Assessment
 
Webinar: Guidance on Industry-led R&D
Webinar: Guidance on Industry-led R&DWebinar: Guidance on Industry-led R&D
Webinar: Guidance on Industry-led R&D
 
Workshop 2 - "Presentation of the concept, definitions and terminology"
Workshop 2  - "Presentation of the concept, definitions and terminology" Workshop 2  - "Presentation of the concept, definitions and terminology"
Workshop 2 - "Presentation of the concept, definitions and terminology"
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
The patients' contribution to ethics committees in the Netherlands
The patients' contribution to ethics committees in the NetherlandsThe patients' contribution to ethics committees in the Netherlands
The patients' contribution to ethics committees in the Netherlands
 
Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...
 
Webinar on EUPATI Guidance for Patient Involvement in Ethical Review of Clini...
Webinar on EUPATI Guidance for Patient Involvement in Ethical Review of Clini...Webinar on EUPATI Guidance for Patient Involvement in Ethical Review of Clini...
Webinar on EUPATI Guidance for Patient Involvement in Ethical Review of Clini...
 
Webinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
Webinar on EUPATI Guidance on Patient Involvement in Regulatory ProcessesWebinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
Webinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
 
Making use of various information systems to disseminate HTA knowledge in France
Making use of various information systems to disseminate HTA knowledge in FranceMaking use of various information systems to disseminate HTA knowledge in France
Making use of various information systems to disseminate HTA knowledge in France
 
Patient involvement prior to regulatory Scientific Advice
Patient involvement prior to regulatory Scientific AdvicePatient involvement prior to regulatory Scientific Advice
Patient involvement prior to regulatory Scientific Advice
 
Engaging with EMA methodology
Engaging with EMA methodology Engaging with EMA methodology
Engaging with EMA methodology
 

Similar to Jornadas #PatientInHTA · Valentina Strammiello

Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
How Effective is the Public in Influencing HTA Decisions?
How Effective is the Public in Influencing HTA Decisions?How Effective is the Public in Influencing HTA Decisions?
How Effective is the Public in Influencing HTA Decisions?Kathi Apostolidis
 
2023 ISPOR Patient Representatives Roundtable - Europe
2023 ISPOR Patient Representatives Roundtable - Europe2023 ISPOR Patient Representatives Roundtable - Europe
2023 ISPOR Patient Representatives Roundtable - Europeipposi
 
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"EURORDIS - Rare Diseases Europe
 
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI
 
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013EUPATI
 
European Cancer Patients Achievements in cancer HTA Advocacy
European Cancer Patients Achievements in cancer HTA AdvocacyEuropean Cancer Patients Achievements in cancer HTA Advocacy
European Cancer Patients Achievements in cancer HTA AdvocacyKathi Apostolidis
 
Alpha One Conference - IPPOSI
Alpha One Conference - IPPOSIAlpha One Conference - IPPOSI
Alpha One Conference - IPPOSIipposi
 
The manifesto for the empowerment to "Produce a joint declaration on the empo...
The manifesto for the empowerment to "Produce a joint declaration on the empo...The manifesto for the empowerment to "Produce a joint declaration on the empo...
The manifesto for the empowerment to "Produce a joint declaration on the empo...Cittadinanzattiva onlus
 
The Pursuit of Precision Healthcare-Patient needs in personalized healthcare
The Pursuit of Precision Healthcare-Patient needs in personalized healthcareThe Pursuit of Precision Healthcare-Patient needs in personalized healthcare
The Pursuit of Precision Healthcare-Patient needs in personalized healthcareKathi Apostolidis
 
Joint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceJoint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceDutch Orphan Drug Network
 
Patients at the Centre of Patient Safety byEPF
Patients at the Centre of Patient Safety byEPFPatients at the Centre of Patient Safety byEPF
Patients at the Centre of Patient Safety byEPFAtlantic Training, LLC.
 
Patients at the Centre of Patient Safety by EPF
Patients at the Centre of Patient Safety by EPFPatients at the Centre of Patient Safety by EPF
Patients at the Centre of Patient Safety by EPFAtlantic Training, LLC.
 
HTA training - Jennifer Dickson, Scottich Medicines Consortium - July 26th 2016
HTA training - Jennifer Dickson, Scottich Medicines Consortium - July 26th 2016HTA training - Jennifer Dickson, Scottich Medicines Consortium - July 26th 2016
HTA training - Jennifer Dickson, Scottich Medicines Consortium - July 26th 2016ipposi
 
Liberating the nhs gp consortia workshop - pam smith
Liberating the nhs gp consortia   workshop - pam smithLiberating the nhs gp consortia   workshop - pam smith
Liberating the nhs gp consortia workshop - pam smithSWF
 

Similar to Jornadas #PatientInHTA · Valentina Strammiello (20)

1 engaging with ema methodology and support
1 engaging with ema methodology and support1 engaging with ema methodology and support
1 engaging with ema methodology and support
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
How Effective is the Public in Influencing HTA Decisions?
How Effective is the Public in Influencing HTA Decisions?How Effective is the Public in Influencing HTA Decisions?
How Effective is the Public in Influencing HTA Decisions?
 
2023 ISPOR Patient Representatives Roundtable - Europe
2023 ISPOR Patient Representatives Roundtable - Europe2023 ISPOR Patient Representatives Roundtable - Europe
2023 ISPOR Patient Representatives Roundtable - Europe
 
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
Workshop 5 - "Feedback from the 15 National Conferences on social aspects"
 
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
 
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
 
European Cancer Patients Achievements in cancer HTA Advocacy
European Cancer Patients Achievements in cancer HTA AdvocacyEuropean Cancer Patients Achievements in cancer HTA Advocacy
European Cancer Patients Achievements in cancer HTA Advocacy
 
Medical devices from patients' perspectives
Medical devices from patients' perspectivesMedical devices from patients' perspectives
Medical devices from patients' perspectives
 
Alpha One Conference - IPPOSI
Alpha One Conference - IPPOSIAlpha One Conference - IPPOSI
Alpha One Conference - IPPOSI
 
The manifesto for the empowerment to "Produce a joint declaration on the empo...
The manifesto for the empowerment to "Produce a joint declaration on the empo...The manifesto for the empowerment to "Produce a joint declaration on the empo...
The manifesto for the empowerment to "Produce a joint declaration on the empo...
 
The Pursuit of Precision Healthcare-Patient needs in personalized healthcare
The Pursuit of Precision Healthcare-Patient needs in personalized healthcareThe Pursuit of Precision Healthcare-Patient needs in personalized healthcare
The Pursuit of Precision Healthcare-Patient needs in personalized healthcare
 
Joint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceJoint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task Force
 
Patient Perspectives on Healthcare in Europe
Patient Perspectives on Healthcare in EuropePatient Perspectives on Healthcare in Europe
Patient Perspectives on Healthcare in Europe
 
Patients at the Centre of Patient Safety byEPF
Patients at the Centre of Patient Safety byEPFPatients at the Centre of Patient Safety byEPF
Patients at the Centre of Patient Safety byEPF
 
Patients at the Centre of Patient Safety by EPF
Patients at the Centre of Patient Safety by EPFPatients at the Centre of Patient Safety by EPF
Patients at the Centre of Patient Safety by EPF
 
CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?
 
HTA training - Jennifer Dickson, Scottich Medicines Consortium - July 26th 2016
HTA training - Jennifer Dickson, Scottich Medicines Consortium - July 26th 2016HTA training - Jennifer Dickson, Scottich Medicines Consortium - July 26th 2016
HTA training - Jennifer Dickson, Scottich Medicines Consortium - July 26th 2016
 
Essencial Project in Catalonia. Avoiding low-value clinical practices
Essencial Project in Catalonia. Avoiding low-value clinical practicesEssencial Project in Catalonia. Avoiding low-value clinical practices
Essencial Project in Catalonia. Avoiding low-value clinical practices
 
Liberating the nhs gp consortia workshop - pam smith
Liberating the nhs gp consortia   workshop - pam smithLiberating the nhs gp consortia   workshop - pam smith
Liberating the nhs gp consortia workshop - pam smith
 

More from Instituto Aragonés de Ciencias de la Salud - IACS

More from Instituto Aragonés de Ciencias de la Salud - IACS (18)

Jornadas #PatientInHTA · Gaizka Benguria
Jornadas #PatientInHTA · Gaizka BenguriaJornadas #PatientInHTA · Gaizka Benguria
Jornadas #PatientInHTA · Gaizka Benguria
 
Sesiones Clínicas de Investigación e Innovación 2017. Huesca
Sesiones Clínicas de Investigación e Innovación 2017. HuescaSesiones Clínicas de Investigación e Innovación 2017. Huesca
Sesiones Clínicas de Investigación e Innovación 2017. Huesca
 
Tipos de proyectos que deben ser evaluados por un CEIC
Tipos de proyectos que deben ser evaluados por un CEICTipos de proyectos que deben ser evaluados por un CEIC
Tipos de proyectos que deben ser evaluados por un CEIC
 
Tipos de CEI
Tipos de CEITipos de CEI
Tipos de CEI
 
Marco normativo de los ensayos clínicos. Novedades RD 1090/2015
Marco normativo de los ensayos clínicos. Novedades RD 1090/2015Marco normativo de los ensayos clínicos. Novedades RD 1090/2015
Marco normativo de los ensayos clínicos. Novedades RD 1090/2015
 
Aspectos críticos en un proyecto de investigación clínica. Consideraciones al...
Aspectos críticos en un proyecto de investigación clínica. Consideraciones al...Aspectos críticos en un proyecto de investigación clínica. Consideraciones al...
Aspectos críticos en un proyecto de investigación clínica. Consideraciones al...
 
Comités de ética en la investigación con animales
Comités de ética en la investigación con animalesComités de ética en la investigación con animales
Comités de ética en la investigación con animales
 
Integridad científica
Integridad científicaIntegridad científica
Integridad científica
 
Cómo elaborar una hoja de información para recabar el consentimiento informado
Cómo elaborar una hoja de información para recabar el consentimiento informadoCómo elaborar una hoja de información para recabar el consentimiento informado
Cómo elaborar una hoja de información para recabar el consentimiento informado
 
Qué hace que una investigación sea ética
Qué hace que una investigación sea éticaQué hace que una investigación sea ética
Qué hace que una investigación sea ética
 
Biobancos y colecciones de muestras biologicas
Biobancos y colecciones de muestras biologicasBiobancos y colecciones de muestras biologicas
Biobancos y colecciones de muestras biologicas
 
Aspectos éticos. Novedades RD 1090/2015
Aspectos éticos. Novedades RD 1090/2015Aspectos éticos. Novedades RD 1090/2015
Aspectos éticos. Novedades RD 1090/2015
 
Manejo de datos en investigacion clinica. Aspectos éticos y legales
Manejo de datos en investigacion clinica. Aspectos éticos y legalesManejo de datos en investigacion clinica. Aspectos éticos y legales
Manejo de datos en investigacion clinica. Aspectos éticos y legales
 
Compra Publica de Innovacion: Proyecto Piloto "Descontaminacion barranco de B...
Compra Publica de Innovacion: Proyecto Piloto "Descontaminacion barranco de B...Compra Publica de Innovacion: Proyecto Piloto "Descontaminacion barranco de B...
Compra Publica de Innovacion: Proyecto Piloto "Descontaminacion barranco de B...
 
Compra Pública de Innovacion. Estructura de gobernanza
Compra Pública de Innovacion. Estructura de gobernanzaCompra Pública de Innovacion. Estructura de gobernanza
Compra Pública de Innovacion. Estructura de gobernanza
 
Estrategia de Compra Publica de Innovación en Aragón: Formación
Estrategia de Compra Publica de Innovación en Aragón: FormaciónEstrategia de Compra Publica de Innovación en Aragón: Formación
Estrategia de Compra Publica de Innovación en Aragón: Formación
 
8. Evaluar tecnologías basadas en mHealth. ¿Es posible un marco común de eval...
8. Evaluar tecnologías basadas en mHealth. ¿Es posible un marco común de eval...8. Evaluar tecnologías basadas en mHealth. ¿Es posible un marco común de eval...
8. Evaluar tecnologías basadas en mHealth. ¿Es posible un marco común de eval...
 
7. Análisis coste-efectividad: ¿un umbral para determinar si el coste de una ...
7. Análisis coste-efectividad: ¿un umbral para determinar si el coste de una ...7. Análisis coste-efectividad: ¿un umbral para determinar si el coste de una ...
7. Análisis coste-efectividad: ¿un umbral para determinar si el coste de una ...
 

Recently uploaded

Session-16-HIV-and-Replacement-Feeding-revised-2012.ppt
Session-16-HIV-and-Replacement-Feeding-revised-2012.pptSession-16-HIV-and-Replacement-Feeding-revised-2012.ppt
Session-16-HIV-and-Replacement-Feeding-revised-2012.pptMedidas Medical Center INC
 
Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.Brian Locke
 
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.pdamico1
 
clostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptx
clostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptxclostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptx
clostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptxMuzammil Ahmed Siddiqui
 
mHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes NextmHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes NextLevi Shapiro
 
Mental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationMental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationStartupSprouts.in
 
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Levi Shapiro
 
Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdf
Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdfTortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdf
Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdfDr. Afreen Nasir
 
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptxSession-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptxMedidas Medical Center INC
 
Homeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdf
Homeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdfHomeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdf
Homeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdfDharma Homoeopathy
 
Giudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdfGiudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdfDr. Afreen Nasir
 
Pulse Check Decisions - RRT and Code Blue Workshop
Pulse Check Decisions - RRT and Code Blue WorkshopPulse Check Decisions - RRT and Code Blue Workshop
Pulse Check Decisions - RRT and Code Blue WorkshopBrian Locke
 
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.pdamico1
 
PSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdf
PSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdfPSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdf
PSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdfkeerti Gour (PT) Shakya
 
Clinical pharmacy book by parthasarathi.pdf
Clinical pharmacy book by  parthasarathi.pdfClinical pharmacy book by  parthasarathi.pdf
Clinical pharmacy book by parthasarathi.pdfDr. Afreen Nasir
 
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxPhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxBlake100757
 
Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...
Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...
Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...Dr. Afreen Nasir
 
Breaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder TreatmentsBreaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder TreatmentsOppositional Defiant Disorder
 

Recently uploaded (20)

Session-16-HIV-and-Replacement-Feeding-revised-2012.ppt
Session-16-HIV-and-Replacement-Feeding-revised-2012.pptSession-16-HIV-and-Replacement-Feeding-revised-2012.ppt
Session-16-HIV-and-Replacement-Feeding-revised-2012.ppt
 
Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.
 
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
 
clostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptx
clostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptxclostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptx
clostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptx
 
mHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes NextmHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes Next
 
Mental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationMental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck Presentation
 
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
 
Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdf
Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdfTortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdf
Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdf
 
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptxSession-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptx
 
Homeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdf
Homeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdfHomeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdf
Homeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdf
 
Giudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdfGiudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdf
 
Session-10-Infants-with-Special-meeds.ppt
Session-10-Infants-with-Special-meeds.pptSession-10-Infants-with-Special-meeds.ppt
Session-10-Infants-with-Special-meeds.ppt
 
Pulse Check Decisions - RRT and Code Blue Workshop
Pulse Check Decisions - RRT and Code Blue WorkshopPulse Check Decisions - RRT and Code Blue Workshop
Pulse Check Decisions - RRT and Code Blue Workshop
 
LTM Session-8-Practices-that-assist-BF..ppt
LTM Session-8-Practices-that-assist-BF..pptLTM Session-8-Practices-that-assist-BF..ppt
LTM Session-8-Practices-that-assist-BF..ppt
 
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
 
PSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdf
PSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdfPSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdf
PSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdf
 
Clinical pharmacy book by parthasarathi.pdf
Clinical pharmacy book by  parthasarathi.pdfClinical pharmacy book by  parthasarathi.pdf
Clinical pharmacy book by parthasarathi.pdf
 
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxPhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
 
Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...
Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...
Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...
 
Breaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder TreatmentsBreaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder Treatments
 

Jornadas #PatientInHTA · Valentina Strammiello

  • 1. Zaragoza, 27-28 April 2017 A patient perspective on HTA involvement Valentina Strammiello Programme Managerr PUBLIC HEALTH CONFERENCE 10th anniversary of the Spanish Network of Health Technology Assessment (HTA) Agencies: Insights for collaborative networking Towards Patient and public engagement in HTA
  • 2. European Patients’ Forum: • Umbrella organisation • active since 2003 • 74 member organisations Mission “To ensure that the patient community drives health policies and programmes that are adapted for their final users, patients.” EPF’s vision is high-quality, patient-centred, and equitable health and social care for all patients across the EU. GOAL #2 To contribute to improvements in health systems that enable equitable access to sustainable and high-quality healthcare designed and delivered to meet patients’ and informal carers’ needs at all levels of care, embracing innovation in all its forms About EPF
  • 3. Helicopter view of patient involvement in HTA in other European HTA agencies or (should be working) Who and how is involved or should be involved, in which stages of the HTA Main difficulties and challenges faced in patient engagement in HTA for a proper patient participation and how they could be addressed Overview of my presentation
  • 4.  Availability of funds/affordability  NHS system (full universal coverage? Bismarckian? Beveridge?)  Who conducts the assessments? Who decides?  Some MS have independent review bodies, others have entities under government mandates No standard methodology at EU level (yet)  Technologies considered for HTA (pharma products and/or medical devices, procedures etc) Helicopter view of patient involvement in HTA in other European HTA agencies = chronic condition ≠ treatments
  • 5. Who did it first in Europe? France and Spain Started in the early ’80 • Since 2016 France –through HAS (Haute Autorité de Santé)- has started a pilot project on patient involvement in HTA • In a questionnaire patients assess whether treatments meet their expectations, report how they cope with their conditions, and impact on quality of life • The project focuses on selected conditions • So far results seems not to be optimal for patient organisations
  • 6. Institute for Quality and Efficiency in Health Care (IQWiG) (assessments) Federal Joint Committee- G-BA (appraisals) Procedures: inclusive priority setting G-BA sub-committees appraise evidence (patients* included, but no voting rights) • G-BA board issues binding decision for sickness funds • If patient representative’s position differs from the board’s decision, this is noted in final documentation and they may take part in press conference to explain their position *Nominated by national umbrella organisation of self-help groups – pool of approximately 300 Who claims they do it better Germany
  • 7. • IQWiG generally invites patient reps to provide input, mainly when patient-relevant outcomes are defined for a protocol • Anyone can submit comments on IQWiG draft protocols and draft reviews during 4-week consultation period • GBA makes open requests for evidence on website and posts to stakeholders (including patient organisations) allowing 1 month for submission Patient input in Germany
  • 8. • NHS Centre for Reviews and Dissemination (Assessments) • National Institute for Health and Clinical Excellence (Appraisals) – Patient involvement units • Scottish Medicines Consortium (SMC) – Decision making Committees – Involvement of lay citizens/ patient representatives – National policy that patients must be involved in healthcare decision-making – SMC Patient & Public Involvement Group (PAPIG) – Development of submission form for patients – Public Involvement Officer supports evidence submissions and provides feedback – Plain English explanations of SMC process Who does it better? UK- England and Scotland
  • 9. Rationale: lack of resources to ensure patients access to innovative technologies Countries involved: – Bulgaria (lead), Croatia, Hungary, Romania, Slovakia • But in the future also: Bosnia and Herzegovina, Macedonia, Serbia, Slovenia – Who is involved in the Think Tank: • Experts, medical doctors, pharmaco-economists, and representatives from patient associations A bottom up regional initiative in Eastern Europe Central Eastern Europe Think Tank on Patient Access-CEE TTPA
  • 10. • HTA Network Patient and Consumer Stakeholder Pool • Patients organisations collaborating with EUnetHTA • EPF informal Working Group on HTA • HTAi PCIG-Patient Panel Patients actions at EU/international level
  • 11. Who and how is involved or should be involved, in which stages of the HTA
  • 12. Patient involvement in HTA • Scoping • Prioritisation • Assessment • Follow up • Role of patient organisations and individual patients • not a thick the box exercise
  • 13. Patient involvement in the HTA life cycle
  • 14.
  • 15. • Time • Language • Patients perceived as a burden /passive actor • Involve and inform about the full life cycle • Education • Build connection with patient organisations Challenges faced in patient engagement in HTA for a proper patient participation
  • 16. /europeanpatientsforum /eupatientsforum More information www.eu-patient.eu info@eu-patient.eu THANK YOU FOR YOUR ATTENTION! Follow us on Social Media! /eupatient eu-patient.eu/blog